LLY

1,024.63

-0.71%↓

JNJ

240.77

+0.94%↑

ABBV

221.51

-1.29%↓

NVS

159.95

+1.01%↑

MRK

118.67

+1.51%↑

LLY

1,024.63

-0.71%↓

JNJ

240.77

+0.94%↑

ABBV

221.51

-1.29%↓

NVS

159.95

+1.01%↑

MRK

118.67

+1.51%↑

LLY

1,024.63

-0.71%↓

JNJ

240.77

+0.94%↑

ABBV

221.51

-1.29%↓

NVS

159.95

+1.01%↑

MRK

118.67

+1.51%↑

LLY

1,024.63

-0.71%↓

JNJ

240.77

+0.94%↑

ABBV

221.51

-1.29%↓

NVS

159.95

+1.01%↑

MRK

118.67

+1.51%↑

LLY

1,024.63

-0.71%↓

JNJ

240.77

+0.94%↑

ABBV

221.51

-1.29%↓

NVS

159.95

+1.01%↑

MRK

118.67

+1.51%↑

Home・Aktien・Pliant Therapeutics Inc

Pliant Therapeutics Inc

Open

1.14 -3.39

Buy Sell

Übersicht

Veränderung der Aktienkurses

24h

Aktuell

Min

1.12

Max

1.21

Schlüsselkennzahlen
By Trading Economics
Einkommen	17M -26M
Angestellte	171
EBITDA	19M -23M

Dividenden
By Dow Jones
Nächstes Ergebnis	26. Feb. 2026

Marktstatistiken
By TradingEconomics
Marktkapitalisierung	-29M 73M
Vorheriger Eröffnungskurs	4.53
Vorheriger Schlusskurs	1.14

Technischer Score

By Trading Central

Vertrauen

Very Strong Bearish Evidence

1.43 / 1.6 Unterstützung & Widerstand

Pliant Therapeutics Inc Chart

Vergangene Performances sind kein verlässlicher Indikator für zukünftige Ergebnisse.

Ähnliche Nachrichten

10. Feb. 2026, 23:26 UTC

Wichtige Markttreiber

Moderna Stock Slips After FDA Refuses Flu Vaccine Review

10. Feb. 2026, 22:31 UTC

Ergebnisse

Correction to America Movil 4Q Profit Article

10. Feb. 2026, 22:22 UTC

Ergebnisse

America Movil 4Q Profit Jumps on Lower Financial Costs

10. Feb. 2026, 23:51 UTC

Market Talk

Ergebnisse

Commonwealth Bank's Margin Management Gives It a Platform -- Market Talk

10. Feb. 2026, 23:42 UTC

Market Talk

Gold Rises Amid Fed Rate-Cut Prospects -- Market Talk

10. Feb. 2026, 23:40 UTC

Market Talk

Ergebnisse

Commonwealth Bank Bear Says 1H Result Looks Strong -- Market Talk

10. Feb. 2026, 23:21 UTC

Market Talk

Ford Says EV Shift Was Driven by Demand Changes -- Market Talk

10. Feb. 2026, 23:21 UTC

Market Talk

Global Equities Roundup: Market Talk

10. Feb. 2026, 22:17 UTC

Market Talk

Australia's One Nation Now Commands Working Class Vote -- Market Talk

10. Feb. 2026, 22:15 UTC

Ergebnisse

Humana Earnings Will Shed More Light on Medicare Prospects -- Barrons.com

10. Feb. 2026, 22:10 UTC

Ergebnisse

Intact Financial 4Q Book Value Per Share Was C$107.35 >IFC.T

10. Feb. 2026, 22:10 UTC

Ergebnisse

Intact Financial Raises Qtr Dividend to C$1.47 >IFC.T

10. Feb. 2026, 22:09 UTC

Ergebnisse

Intact Financial 4Q Combined Ratio Was 85.9% >IFC.T

10. Feb. 2026, 22:09 UTC

Ergebnisse

Intact Financial 4Q Adj EPS C$5.50 >IFC.T

10. Feb. 2026, 22:01 UTC

Ergebnisse

Intact Financial 4Q EPS C$5.24 >IFC.T

10. Feb. 2026, 21:54 UTC

Ergebnisse

James Hardie Industries Sees FY26 Total Adjusted EBITDA $1.232B to $1.263B >JHX

10. Feb. 2026, 21:53 UTC

Ergebnisse

Robinhood Stock Tumbles as Crypto-Related Revenue Falls Short of Expectations -- Barrons.com

10. Feb. 2026, 21:51 UTC

Ergebnisse

James Hardie Industries Sees FY26 Free Cash Flow at Least $200M

10. Feb. 2026, 21:51 UTC

Ergebnisse

Gilead Earnings Surprise. Why The Stock Is Tumbling Anyway. -- Barrons.com

10. Feb. 2026, 21:51 UTC

Ergebnisse

James Hardie Industries: Focused on the Achievement of $125 M Target >JHX

10. Feb. 2026, 21:51 UTC

Ergebnisse

James Hardie Industries: Integration and Cost Synergies Ahead of Schedule >JHX

10. Feb. 2026, 21:51 UTC

Ergebnisse

Akquisitionen, Fusionen, Übernahmen

Evolution Net Debt A$362 Million at Dec. 31 Vs A$1.29 Billion Year Earlier

10. Feb. 2026, 21:50 UTC

Ergebnisse

Akquisitionen, Fusionen, Übernahmen

Evolution: Gearing 6% at Dec. 31, From 23% a Year Earlier

10. Feb. 2026, 21:50 UTC

Ergebnisse

James Hardie Industries 3Q EPS 12c >JHX

10. Feb. 2026, 21:50 UTC

Market Talk

Basic Materials Roundup: Market Talk

10. Feb. 2026, 21:50 UTC

Ergebnisse

James Hardie Industries 3Q Adj EPS 24c >JHX

10. Feb. 2026, 21:49 UTC

Ergebnisse

James Hardie Industries 3Q Sales $1.24B >JHX

10. Feb. 2026, 21:49 UTC

Ergebnisse

Akquisitionen, Fusionen, Übernahmen

Evolution 1H Operating Mine Cash Flow a Record A$1.73 Billion

10. Feb. 2026, 21:48 UTC

Ergebnisse

Akquisitionen, Fusionen, Übernahmen

Evolution 1H Ebitda A$1.56 Billion, Up 59% On-Year

10. Feb. 2026, 21:47 UTC

Ergebnisse

Akquisitionen, Fusionen, Übernahmen

Evolution 1H Revenue A$2.79 Billion, Up 37% On-Year

Peer-Vergleich

Kursveränderung

Pliant Therapeutics Inc Prognose

Rating-Konsens

By TipRanks

Sell

1 ratings

Buy

Halten

Sell

Basierend auf 1 Analysten, die in den letzten 3 Monaten Aktienbewertungen für Pliant Therapeutics Inc – Dist abgegeben haben.

Technischer Score

By Trading Central

1.43 / 1.6Unterstützung & Widerstand

Recent bearish events outweigh bullish events.

There is one bearish event.

Finanzen

Vertriebs- und Verwaltungskosten

Betriebsaufwand

Gewinn vor Steuern

Verkäufe

Umsatzkosten

Bruttogewinn aus dem Verkauf

Zinsaufwand für Schulden

EBITDA

Betriebsergebnis

Über Pliant Therapeutics Inc

Pliant Therapeutics, Inc., a clinical stage biopharmaceutical company, discovers, develops, and commercializes novel therapies for the treatment of fibrosis and related diseases in the United States. The company's lead candidate is bexotegrast, an oral, small-molecule, dual selective inhibitor of avß6 and avß1 integrins, which is in phase 2b trials for idiopathic pulmonary fibrosis and in phase 2a trial for primary sclerosing cholangitis. It also develops PLN-1474, an oral, small-molecule selective inhibitor of avß1 for the treatment of liver fibrosis associated with nonalcoholic steatohepatitis; PLN-101095, a dual inhibitor of integrins avß8 and avß1 for the treatment of solid tumors; and PLN-101325 for treatment of muscular dystrophies. Pliant Therapeutics, Inc. was incorporated in 2015 and is based in South San Francisco, California.